CA2162557A1 - Conserved motif of hepatitis c virus e2/ns1 region - Google Patents

Conserved motif of hepatitis c virus e2/ns1 region

Info

Publication number
CA2162557A1
CA2162557A1 CA002162557A CA2162557A CA2162557A1 CA 2162557 A1 CA2162557 A1 CA 2162557A1 CA 002162557 A CA002162557 A CA 002162557A CA 2162557 A CA2162557 A CA 2162557A CA 2162557 A1 CA2162557 A1 CA 2162557A1
Authority
CA
Canada
Prior art keywords
region
motif
virus
hcv
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002162557A
Other languages
French (fr)
Other versions
CA2162557C (en
Inventor
Amy J. Weiner
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22037528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2162557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2162557A1 publication Critical patent/CA2162557A1/en
Application granted granted Critical
Publication of CA2162557C publication Critical patent/CA2162557C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Abstract

The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein F2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.
CA002162557A 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region Expired - Fee Related CA2162557C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12
US08/061,699 1993-05-12
PCT/US1994/004853 WO1994026306A1 (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Publications (2)

Publication Number Publication Date
CA2162557A1 true CA2162557A1 (en) 1994-11-24
CA2162557C CA2162557C (en) 2004-09-28

Family

ID=22037528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162557A Expired - Fee Related CA2162557C (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Country Status (7)

Country Link
US (6) US6692907B1 (en)
EP (2) EP0697888B1 (en)
JP (3) JPH08510240A (en)
AT (1) ATE249838T1 (en)
CA (1) CA2162557C (en)
DE (1) DE69433160T2 (en)
WO (1) WO1994026306A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE249838T1 (en) * 1993-05-12 2003-10-15 Chiron Corp PRESERVED MOTIF OF THE HEPATITIS C VIRUS E2/NS1 REGION
DE19504302A1 (en) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Method for serological typing using type-specific antigens
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (en) * 1996-03-19 1997-10-13 성재갑 Secretory envelope proteins 1 and 2 of hepatitis C virus (Japanese type)
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
AU7602800A (en) * 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
CN100391469C (en) * 2000-02-14 2008-06-04 三菱制药株式会社 Remedies for hepatitis C
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (en) 2011-12-20 2016-12-30 Bio-Rad Innovations METHOD FOR DETECTING HEPATITIS C VIRUS INFECTION
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
ZA814386B (en) * 1980-07-01 1982-07-28 Nat Res Dev Production of viral antigens
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
DE3382547D1 (en) 1983-01-12 1992-05-27 Chiron Corp SECRETORIC EXPRESSION IN EUKARYOTS.
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
DE318216T1 (en) 1987-11-18 1990-06-13 Chiron Corp., Emeryville, Calif., Us NANBV DIAGNOSTICS AND VACCINE.
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
UA50829C2 (en) 1989-03-17 2002-11-15 Чірон Корпорейшн Polynucleotide, vector, cells, expressing system, polypeptides, monoclonal antibodies, preparation of polyclonal antibodies, nucleotide probe, analytic kits, method for detecting nucleic acids, methods for immunoassay, vaccine, method for production of antibodies
RO113059B1 (en) 1989-05-18 1998-03-30 Chiron Corp Polynucleotide capable of hybridizing on a hcv sequence, method for detecting a hcv sequence and process for removing hcv from blood
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2203443C (en) * 1990-11-08 2001-08-28 Robert O. Ralston Hepatitis c virus asialoglycoproteins
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
DE69232859T2 (en) * 1991-09-13 2003-04-10 Chiron Corp COMPOSITION OF SEVERAL IMMUNE REACTIVE HEPATITIS C VIRUS POLYPEPTIDES
EP0583481B1 (en) 1992-02-05 1999-11-10 Daikin Industries, Ltd. Polytetrafluoroethylene powder for molding
BR9305435A (en) 1992-03-06 1994-12-27 Innogenetics Nv Process for determining peptides corresponding to immunologically important epitopes and their use in a process for determining biotinylated antibodies or peptides corresponding to immunologically important epitopes, process for preparing them and compositions containing them
ATE249838T1 (en) * 1993-05-12 2003-10-15 Chiron Corp PRESERVED MOTIF OF THE HEPATITIS C VIRUS E2/NS1 REGION
AU698878B2 (en) 1993-11-04 1998-11-12 Genimmune N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
HU228873B1 (en) * 2000-06-15 2013-06-28 Novartis Vaccines & Diagnostic Hcv antigen/antibody combination assay

Also Published As

Publication number Publication date
US20030017156A1 (en) 2003-01-23
EP1421951A3 (en) 2005-10-05
EP0697888B1 (en) 2003-09-17
DE69433160T2 (en) 2004-07-08
DE69433160D1 (en) 2003-10-30
JP2005325126A (en) 2005-11-24
US7371386B2 (en) 2008-05-13
US7098303B1 (en) 2006-08-29
ATE249838T1 (en) 2003-10-15
US6692907B1 (en) 2004-02-17
US7135185B1 (en) 2006-11-14
WO1994026306A1 (en) 1994-11-24
EP0697888A1 (en) 1996-02-28
CA2162557C (en) 2004-09-28
US7252827B1 (en) 2007-08-07
JP2005097319A (en) 2005-04-14
EP1421951A2 (en) 2004-05-26
JPH08510240A (en) 1996-10-29
US20070014813A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CA2162557A1 (en) Conserved motif of hepatitis c virus e2/ns1 region
WO1995012677A3 (en) Immunodominant human t-cell epitopes of hepatitis c virus
EP1076092A3 (en) Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents
EP0984067A3 (en) Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
CA2032381A1 (en) Viral agent
CA2110058A1 (en) Hepatitis c virus (hcv) polypeptides
CA2127541A1 (en) Recombinant swinepox virus
EP1016708A4 (en) Yeast extract composition, yeast for obtaining the same, and process for producing yeast extract composition
DE3588254D1 (en) Gag antigen and its use for the detection of LAV infection, as well as in immunogenic compositions
DE69739268D1 (en) PREPARATION AND CLEANING OF HEPATITIS C VIRUS-RELATED PARTICLES
CA2116764A1 (en) Immunoreactive Hepatitis C Virus Polypeptide Compositions
WO1992010514A3 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
CA2140531A1 (en) Method of Increasing Expression of Viral Proteins
CA2065287A1 (en) New hcv isolates
EP0328403A3 (en) Synthetic peptides related to the hiv-gp120-env-protein, and their use
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
WO1991009872A3 (en) Hiv-1 env fragment fusion protein
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
HU910069D0 (en) Process for the production of non-a, non-b hepathitis virus genomial dna and antigene polypeptide
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
CA2065022A1 (en) Rubella peptides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130503